AGP Picks
View all

Catch up with health and wellness news from Cabo Verde

Provided by AGP

Health Wire Cabo Verde: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Cabo Verde.

Press releases published on May 18, 2026

 Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
PsyMetrics Releases Healthcare Workforce Benchmark Showing Up to 67% Reduction in Hospital Staff Turnover
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Certara to Participate in Upcoming Investor Conferences
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DeGen Medical Expands Patient-Specific Spine Platform
Memopezil Claims Evaluated (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD  
Communiqué de presse : ATS : Les données de phase 2 démontrent la supériorité de l'efdoralprin alfa par rapport au traitement de substitution standard pour atteindre des taux de fAAT plus élevés dans le DAAT
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

Share us

on your social networks:

Sign up for:

Health Wire Cabo Verde

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.